ProfileGDS5678 / 1456647_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 30% 31% 31% 30% 30% 41% 35% 30% 30% 30% 30% 30% 30% 30% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.7173730
GSM967853U87-EV human glioblastoma xenograft - Control 22.6915731
GSM967854U87-EV human glioblastoma xenograft - Control 32.6980531
GSM967855U87-EV human glioblastoma xenograft - Control 42.6357630
GSM967856U87-EV human glioblastoma xenograft - Control 52.6334330
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.0285841
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.8440935
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.6736130
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.6546930
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.6787630
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.6813130
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.6614330
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.6859230
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.6823730